Editing Thalidomide (section)

=== Interactions ===
There are no expected [[Pharmacokinetics|pharmacokinetic]] interactions between thalidomide and other medicines due to its neutral effects on [[P-glycoprotein]] and the [[cytochrome P450]] family.  It may interact with sedatives due to its sedative action and bradycardic agents, like beta-blockers, due to its bradycardia-inducing effects. The risk of [[peripheral neuropathy]] may be increased by concomitant treatment of thalidomide with other agents known to cause peripheral neuropathy.<ref name="TGA">{{Cite web |date=21 June 2013 |title=THALOMID® CAPSULES |url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03581-3 |url-status=live |archive-url=https://web.archive.org/web/20150904052354/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03581-3 |archive-date=4 September 2015 |access-date=17 January 2014 |website=TGA eBusiness Services |publisher=Celgene Pty Limited |format=PDF}}</ref> The risk of [[venous thromboembolism]]s with thalidomide seems to be increased when patients are treated with [[oral contraceptives]] or other cytotoxic agents (including [[doxorubicin]] and [[melphalan]]) concurrently. Thalidomide may interfere with various contraceptives, and hence it is advised that women of reproductive age use at least two different means of contraception to ensure that no child will be conceived while they are taking thalidomide.<ref name=UKlabel2017/><ref name=USlabel2017/><ref name = TGA/>